**Supplementary Materials:** Demographic Gaps and Requirements for Participation: A Systematic Review of Clinical Trial Designs in Hidradenitis Suppurativa

JaBreia Fanita James, BS; Victoria M. Madray, MD; Nicole Salame, MD; Samar Babikir Hasan, MD;Mia Sohn White, MILS; Jason Richard Barron, MPH; Joslyn Kirby, MD MEd MS; John Robert Ingram, MD; Lauren Anne Vigil Orenstein, MD MScb

**TABLE OF CONTENTS**

SUPPLEMENTAL TABLE 1. Characteristics of Hidradenitis Suppurativa Randomized Controlled Trials…….**Page 2**

SUPPLEMENTAL TABLE 2: Other patient groups excluded due to medical co-morbidities………….....…......**Page 4**

SUPPLEMENTAL FIGURE 1: Summary of literature search and study selection …………………..…………**Page 5**

APPENDIX 1: Literature Search Strategies...…………………………………………………..………………….**Page 6**

References for Supplemental Materials ………………...…………………………………………………………**Page 8**

**Supplemental Table 1. Characteristics of hidradenitis suppurativa randomized controlled trials**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Study** | **N** | **Study years** | **Location** | **Intervention** | **Control** | **Blinding** | **1̊ Outcome** | **Funding** |
| **Pioneer II[**1**]** | 326 | 2011-2014 | Europe and USA | Adalimumab | Placebo | Double | HiSCR[2] | Industry |
| **Pioneer I**[1] | 307 | 2011-2014 | Europe and USA | Adalimumab | Placebo | Double | HiSCR[2] | Industry |
| **Buimer**[3] | 200 | 2008c | Netherlands | Excision and closure with gentamicin sponge | Excision and closure without sponge | NR | Postoperative complications | Investigator initiated |
| **Kimball 2012**[4,5] | 154 | 2009-2010 | Europe and USA | Adalimumab | Placebo | Double | HS-PGA[2,6] | Industry |
| **Jemec**[7] | 46 | 1996-1997b | Denmark | Oral tetracycline + topical placebo | Topical clindamycin + oral placebo | Double | VAS | Industry  Partnership |
| **Yildiz**[8] | 43 | 2012-2014 | Turkey | Hyperbaric oxygen, oral clindamycin + rifampin | Oral clindamycin +rifampin | None | NR | NR |
| **Wilden**[9] | 43 | 2014-2015 | Germany | IPL+RF (LAight®) | RF or IPL | Doublea | Number of inflammatory nodules, abscesses, and draining fistulae | Industry Partnership |
| **Grant**[10] | 38 | 2005-2008 | USA | Infliximab | Placebo | Double | HSSI[4,11] | Investigator Initiated |
| **Naouri[**12] | 36 | 2021c | France | Nd:YAG laser (1064 nm) | No treatment on contralateral side | Single | Number of inflammatory lesions | Investigator Initiated |
| **Fajgenbaum**[13] | 32 | 2016-2017 | USA | Intralesional triamcinolone | Saline injection | Double | Days to resolution of lesions, pain reduction | Investigator Initiated |
| **Angel[**14] | 31 | 1987c | NR | Staphage lysate | Placebo | Double | Decrease in "point system" used to grade severity | Investigator initiated |
| **Mortimer**[15] | 24 | 1986c | United Kingdom | Ethinyloestradiol + cyproterone acetate | Ethinyloestradiol + norgestrel | Double | NR | Industry Partnership |
| **Andersen[**16] | 24d | 2017-2018 | Denmark | IPL (Palomar LuxY, Series II, Cynosure Inc) | No treatment on contralateral side | Single | HiSCR[2] | Investigator Initiated |
| **Mahmoud**[17.18] | 22 | 2007-2009 | USA | Nd:YAG laser (1064 nm) + Topical clindamycin and BPO | Topical clindamycin and BPO | Single | HS-LASI[17] | Investigator initiated |
| **Miller**[19] | 21 | 2007-2010 | Denmark | Adalimumab | Placebo | Double | Sartorius[11]and Hurley scoring systems | Industry Partnership |
| **Adams[**20] | 20 | 2010c | USA | Etanercept | Placebo | Double | 4-point PGA | Industry Partnership |
| **Tzanetakou[**21] | 20e | 2012-2014 | Greece | Anakinra | Placebo | Double | HS disease severity[22] | Investigator Initiated |
| **Kanni[**23] | 20 | 2015-2017 | Greece | MABp1 | Placebo | Double | HiSCR[2] | Industry Partnership |
| **Vossen**[24] | 20 | 2017 | Netherlands | Apremilast | Placebo | Double | HiSCR[2] | Industry |
| **Grimstad**[25] | 20 | 2017-2018 | Norway | BTX-B (NeuroBlock®) | Placebo | Double | DLQI[26] | Investigator Initiated |
| **Azim[**27] | 20 | 2017 | Egypt | Fractional CO2 (10,600nm) + Nd:YAG (1064 nm) | Nd:YAG (1064 nm) | Single | HS-PGA[2,6] | NR |
| **Highton[**28] | 18 | 2011c | United Kingdom | Intense pulsed light (Harmony®) | No treatment on contralateral axilla | Single | Sartorius score[11] | NR |
| **Fadel**[29] | 11 | 2013 | Egypt | IPL (EPI-C Plus ®) + niosomal MB gel | IPL + free MB gel | Single | HS-LASI[17] | Investigator Initiated |

Supplemental Table 1 Key:

BPO: Benzoyl peroxide; BTX: Botulinum Toxin; CRP: C-reactive Protein; DLQI[26]: Dermatology Life Quality Index; ESR: Erythrocyte Sedimentation Rate

HiSCR[2]: Hidradenitis Suppurativa Clinical Response; HS-LASI[17]: Hidradenitis Suppurativa Lesion, Area and Severity Index; HS-PGA[2,6]: Hidradenitis Suppurativa Physician's Global Assessment; HSSI[4,30]: HS Severity Index; IPL: Intense pulsed light; MB: methylene blue; N: number of participants randomized

NR: Not reported; RF: Radiofrequency; US: United States; VAS: Visual Analogue Scale

aOnly patients in the IPL+RF and IPL only groups were blinded.

bFrom private communication with authors.

cPublication date listed, as study dates not reported.

d17 of the 24 randomized participants were included in the final analysis

e 19 of the 20 randomized participants were included in the final analysis

**Supplemental Table 2: Other patients groups excluded due to medical co-morbidities**

|  |  |  |  |
| --- | --- | --- | --- |
| **Study** | **CHF** | **HIV** | **History of Malignancy** |
| **Pioneer II[**1**]** | **✕** | **✕** | **✕** |
| **Pioneer I**[1] | **✕** | **✕** | **✕** |
| **Buimer**[3] | **✓** | **✓** | **✓** |
| **Kimball 2012**[4,5] | **✕** | **✕** | **✕** |
| **Jemec**[7] | **✕**a, b | **✓** | **✓** |
| **Yildiz**[8] | **✕**a | **✓** | **✓** |
| **Wilden**[9] | **✓** | **✓** | **✓** |
| **Grant**[10] | **✕** | **✕** | **✕** |
| **Naouri[**12] | **✓** | **✓** | **✓** |
| **Fajgenbaum**[13] | **✓** | **✓** | **✓** |
| **Angel[**14] | **✓** | **✓** | **✓** |
| **Mortimer**[15] | **✓** | **✓** | **✓** |
| **Andersen[**16] | **✓** | **✓** | **✓** |
| **Mahmoud**[17.18] | **✓** | **✓** | **✓** |
| **Miller**[19] | **✕**b | **✕**b | **✕**b |
| **Adams[**20] | **✕** | **✕** | **✕** |
| **Tzanetakou[**21] | **✓** | **✕** | **✕** |
| **Kanni[**23] | **✓** | **✕** | **✓** |
| **Vossen**[24] | **✕**a | **✕**a | **✕**a |
| **Grimstad**[25] | **✓** | **✓** | **✓** |
| **Azim[**27] | **✕**a | **✕**a | **✕**a |
| **Highton[**28] | **✓** | **✓** | **✓** |
| **Fadel**[29] | **✓** | **✓** | **✓** |
| **Studies with exclusion, n (%)** | **10 (43)** | **10 (43)** | **9 (39)** |

Supplemental Table 2 Key:


HIV: Human Immunodeficiency Virus; CHF: Congestive heart failure

**✓** Included; **✕**Excluded;

aIntervention unlikely to cause harm to this subset of patients based on medical comorbidities

bObtained through personal correspondence with authors

**Supplemental Figure 1: Summary of literature search and study selection**



**Appendix 1: Literature Search Strategies:**

**PubMed (pubmed.gov)**

1. "hidradenitis suppurativa"[MeSH Terms] OR "hidradenitis suppurativa"[TW] OR acne inversa[TW]
2. "Clinical Trial" [Publication Type] OR "Clinical Trials as Topic"[Mesh] OR “clinical trial\*”[TW] OR “controlled clinical trial\*”[TW] OR “randomized clinical trial\*”[TW]
3. #1 AND #2
4. #3 AND English [lang]

**EMBASE (embase.com)**

1. 'suppurative hidradenitis'/exp OR 'hidradentitis supprativa':ti,ab OR 'acne inversa':ti,ab 'clinical trial'/exp OR 'clinical trial\*':ti,ab OR (clinical NEAR/2 trial\*) OR (controlled NEAR/2 ‘clinical trial\*’) OR (randomized NEAR/2 ‘clinical trial\*’)
2. #1 AND #2
3. #3 AND [english]/lim AND ('article'/it OR 'article in press'/it OR 'review'/it)

**Central (cochranelibrary.com)**

1. MeSH descriptor: [Hidradenitis Suppurativa] explode all trees
2. “hidradenitis suppurativa”:ti,ab
3. "acne inversa":ti,ab
4. #1 OR #2 OR #3
5. MeSH descriptor: [Clinical Trial] explode all trees
6. "clinical trial":ti,ab OR clinical NEAR/2 trial\* OR (controlled NEAR/2 “clinical trial\*”) OR (randomized NEAR/2 “clinical trial\*”)
7. #5 OR #6
8. #4 AND #7

**Science Citation Index Expanded**

**Social Sciences Citation Index**

**Arts & Humanities Citation Index**

**Conference Proceedings Citation Index – Science**

**Conference Proceedings Citation Index – Social Science & Humanities**

**Book Citation Index – Science**

**Book Citation Index – Social Sciences & Humanities**

**Emerging Sources Citation Index**

**Current Chemical Reactions**

1. (TS=("hidradenitis suppurativa") OR TS=("acne inversa"))
2. (TS=(clinical NEAR/2 trial\*) OR TS=(controlled NEAR/2 “clinical trial\*”) OR TS=(randomized NEAR/2 “clinical trial\*”))
3. #1 AND #2
4. #3 AND LANGUAGE: (English) AND (Article OR Review)

**Supplemental Reference**

1. Kimball AB, Okun MM, Williams DA, Gottlieb AB, Papp KA, Zouboulis CC, et al. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. N Engl J Med. 2016;375(5):422–34.

2. Kimball AB, Jemec GBE, Yang M, Kageleiry A, Signorovitch JE, Okun MM, et al. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. Br J Dermatol. 2014;171(6):1434–42.

3. Buimer MG, Ankersmit MFP, Wobbes T, Klinkenbijl JHG. Surgical treatment of hidradenitis suppurativa with gentamicin sulfate: A prospective randomized study. Dermatologic Surg. 2008 Feb;34(2):224–7.

4. Kimball AB, Kerdel F, Adams D, Mrowietz U, Gelfand JM, Gniadecki R, et al. Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: A parallel randomized trial. Ann Intern Med. 2012;157(12):846–55.

5. Scheinfeld N, Sundaram M, Teixeira H, Gu Y, Okun M. Reduction in pain scores and improvement in depressive symptoms in patients with hidradenitis suppurativa treated with adalimumab in a phase 2, randomized, placebo-controlled trial. Dermatol Online J. 2016;22(3).

6. Robinson A, Kardos M, Kimball AB. Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): Why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. J Am Acad Dermatol. 2012;66(3):369–75.

7. Jemec GBE, Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 1998;39(6):971–4.

8. Yildiz H, Senol L, Ercan E, Bilgili ME, Karabudak Abuaf O. A prospective randomized controlled trial assessing the efficacy of adjunctive hyperbaric oxygen therapy in the treatment of hidradenitis suppurativa. Int J Dermatol. 2016;55(2):232–7.

9. Wilden S, Friis M, Tuettenberg A, Staubach-Renz P, Wegner J, Grabbe S, et al. Combined treatment of hidradenitis suppurativa with intense pulsed light (IPL) and radiofrequency (RF). J Dermatolog Treat. 2021;32(5):530–7.

10. Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: A randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol. 2010;

11. Sartorius K, Lapins J, Emtestam L, Jemec GBE. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa [11]. Vol. 149, British Journal of Dermatology. 2003. p. 211–3.

12. Naouri M, Maruani A, Lagrange S, Cogrel O, Servy A, Collet Vilette AM, et al. Treatment of hidradenitis suppurativa using a long-pulsed hair removal neodymium:yttrium-aluminium-garnet laser: A multicenter, prospective, randomized, intraindividual, comparative trial. J Am Acad Dermatol. 2021;84(1):203–5.

13. Fajgenbaum K, Crouse L, Dong L, Zeng D, Sayed C. Intralesional Triamcinolone May Not Be Beneficial for Treating Acute Hidradenitis Suppurativa Lesions: A Double-Blind, Randomized, Placebo-Controlled Trial. Dermatologic Surg. 2020;46(5):685–9.

14. Angel MF, Ramasastry SS, Manders EK, Granfield D, Futress JW. Beneficial effects of staphage lysate in the treatment of chronic recurrent hidradenitis suppurativa. Surg Forum. 1987;38:111–2.

15. MORTIMER PS, DAWBER RPR, GALES MA, MOORE RA. A double‐blind controlled cross‐over trial of cyproterone acetate in females with hidradenitis suppurativa. Br J Dermatol. 1986;115(3):263–8.

16. Lindsø Andersen P, Riis PT, Thorlacius L, Sigsgaard V, Nielsen CW, Chafranska L, et al. Intense pulsed light treatment for hidradenitis suppurativa: a within-person randomized controlled trial. Eur J Dermatology. 2020;30(6):723–9.

17. Tierney E, Mahmoud BH, Hexsel C, Ozog D, Hamzavi I. Randomized control trial for the treatment of hidradenitis suppurativa with a neodymium-doped yttrium aluminium garnet laser. Dermatologic Surg. 2009;35(8):1188–98.

18. Mahmoud BH, Tierney E, Hexsel CL, Pui J, Ozog DM, Hamzavi IH. Prospective controlled clinical and histopathologic study of hidradenitis suppurativa treated with the long-pulsed neodymium:yttrium-aluminium-garnet laser. J Am Acad Dermatol. 2010;62(4):637–45.

19. Miller I, Lynggaard CD, Lophaven S, Zachariae C, Dufour DN, Jemec GBE. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa. Br J Dermatol. 2011;165(2):391–8.

20. Adams DR, Yankura JA, Fogelberg AC, Anderson BE. Treatment of hidradenitis suppurativa with etanercept injection. Arch Dermatol. 2010;146(5):501–4.

21. Tzanetakou V, Kanni T, Giatrakou S, Katoulis A, Papadavid E, Netea MG, et al. Safety and efficacy of anakinra in severe hidradenitis suppurativa a randomized clinical trial. JAMA Dermatology. 2016;152(1):52–9.

22. Giamarellos-Bourboulis EJ, Pelekanou E, Antonopoulou A, Petropoulou H, Baziaka F, Karagianni V, et al. An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa. Br J Dermatol. 2008;

23. Kanni T, Argyropoulou M, Spyridopoulos T, Pistiki A, Stecher M, Dinarello CA, et al. MABp1 Targeting IL-1α for Moderate to Severe Hidradenitis Suppurativa Not Eligible for Adalimumab: A Randomized Study. J Invest Dermatol. 2018;138(4):795–801.

24. Vossen ARJV, van Doorn MBA, van der Zee HH, Prens EP. Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial. J Am Acad Dermatol. 2019;80(1):80–8.

25. Grimstad Ø, Kvammen BØ, Swartling C. Botulinum Toxin Type B for Hidradenitis Suppurativa: A Randomised, Double-Blind, Placebo-Controlled Pilot Study. Am J Clin Dermatol [Internet]. 2020;21(5):741–8. Available from: https://doi.org/10.1007/s40257-020-00537-9

26. FINLAY AY, KHAN GK. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–6.

27. Abdel Azim AA, Salem RT, Abdelghani R. Combined fractional carbon dioxide laser and long-pulsed neodymium : yttrium-aluminium-garnet (1064 nm) laser in treatment of hidradenitis suppurativa; a prospective randomized intra-individual controlled study. Int J Dermatol. 2018 Sep 1;57(9):1135–44.

28. Highton L, Chan WY, Khwaja N, Laitung JKG. Treatment of hidradenitis suppurativa with intense pulsed light: A prospective study. Plast Reconstr Surg. 2011;128(2):459–65.

29. Fadel MA, Tawfik AA. New topical photodynamic therapy for treatment of hidradenitis suppurativa using methylene blue niosomal gel: A single-blind, randomized, comparative study. Clin Exp Dermatol. 2015;40(2):116–22.

30. Sartorius K, Killasli H, Heilborn J, Jemec GBE, Lapins J, Emtestam L. Interobserver variability of clinical scores in hidradenitis suppurativa is low. Br J Dermatol. 2010;162(6):1261–8.